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Sentinel lymph node biopsies in patients with malignant melanoma  
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In 1999, the World Health Organisation (WHO) stated that sentinel lymph node biopsy should be the standard of 
management for those patients with melanomas without clinical signs of metastases to the regional lymph nodes. 
This procedure should include preoperative and intraoperative lymphoscintigraphy, combined with staining. Sentinel 
lymph node biopsies should be performed after excision biopsy of the melanoma and simultaneously with radical 
excision of the remaining scar after melanoma excision biopsy. Whenever sentinel lymph node(s) are found tumo-
ur occupied, metastases are most likely to be located in one or more lymph nodes that were first occupied along 
lymphatic drainage from the primary focal point of the cancer. Detecting even single melanoma cells in the sentinel 
lymph node is usually used to determine the stage of the disseminating cancer and radically changes prognoses 
and further therapeutic decisions. Guidelines on lymph nodes examined during melanoma have been established 
by the College of American Pathologists (CAP), the European Society of Pathology (ESP) and the Polish Society of 
Pathologists in 2013. If melanoma metastases are found in sentinel lymph node(s) then: 
 — the number of lymph nodes should be specified as well as the number of those with metastases;
 — microscopic features of sentinel lymph node(s) metastases should be defined as follows: the largest metastasis/ 
/metastases size, their location (subcapsular, intraparenchymal, mixed or extended), signs of possible infiltration 
and crossing the node capsule, penetration into adipose tissue and vasculature involvement. 
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Epidemiology
In Poland, according to the 2013 data of the National 
Cancer Registry, 3027 new cases of skin melanoma were 
reported; 1414 males and 1613 females. The disease caused 
1400 deaths; 739 males and 661 females [1]. In the USA, 
73 870 new cases of this malignancy were diagnosed in 2015 
and 9940 patients died [2]. In Poland, melanoma is a tumour 
whose incidence is very rapidly increasing. 
Pathological-clinical factors
Skin melanoma is a malignant tumour arising from the 
uncontrolled proliferation of cells termed melanocytes, 
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located in the epidermis. The tumour most frequently de-
velops from a primary transformation of those cells which 
settle the epidermis. At the preinvasive stage, melanocytes 
proliferate which is characteristic of the in situ phase of 
radial growth. At the invasive stage, they penetrate into 
the skin forming a vertical phase (nodule). Infiltration of 
the stroma is associated with the risk of dissemination via 
the lymphatic or blood vessels. Hyperplasia in the skin 
lymphatic vessels may cause satellite foci to develop (in-
-transit metastases), and their transfer to lymph nodes; 
metastatic lymphadenopathy. Important prognostic fac-
tors associated with primary tumour features (pT features) 
include [3, 4, 8]:
 — infiltration thickness in mm (according to Breslov);
 — ulceration of significant prognostic value in cases wi-
thout metastases. The presence of ulceration in invasi-
ve melanomas elevates the pT progression stage from 
pT1’a’ to the pT1’b’ substage.
The number of mitotic figures counted only in the ver-
tical plane,(the radial plane not being taken into account), 
in hot spots [3–6] is a prognostic factor but has no effect 
on the pT feature according to the TNM classification of 
2017 [8].
The extent of invasion according to Clark’s classifi-
cation is however of lower prognostic importance [6–8]. 
Apart from the aforementioned prognostic parameters of 
primary melanoma and micrometastases, (in the current 
TNM classification revision of 2017 called ‘clinically occult 
metastases’), to sentinel lymph nodes, particularly at the 
pT1 stage, then they are of prognostic value, especially in 
medium-thickness melanomas without clinically detecta-
ble metastases [8].
Clinical and pathological procedures
Total excision of a primary tumour, along with a margin 
of surrounding tissues is the optimal recommended surgical 
procedure making it possible to establish a pathological 
diagnosis of melanoma as well as assessing prognostic 
factors. The shave technique or punch biopsy of a tumour 
fragment are not recommended, as both methods preclude 
any assessment of tissues at the tumour margin or of de-
tecting microsatellite foci. Pathological assessment of a full 
lesion cross-section is recommended. There are however no 
indications for examining frozen preparations, both from 
the primary lesion and the sentinel lymph node, because 
assessing such material by these means can reduce the 
sensitivity of the examination thereby rendering detection 
of single metastatic cells impossible [7, 10]. 
The clinical procedure used for invasive melanomas 
without clinically detectable metastases upon gross exami-
nation consists of excising the primary lesion with a margin 
of surrounding tissues together with a possibly following-on 
sentinel lymph node (SLN) biopsy. According to patholo-
gical indications, the examination should be performed 
following the standard procedure after fixing the tissue 
material in buffered 10% formalin solution, processing it 
to paraffin blocks and routinely staining the preparations 
with haematoxylin and eosin with possible application of 
immunophenotyping [4, 5, 11].
Patients are qualified for sentinel lymph node biopsy 
without clinical signs of metastases to regional lymph nodes 
and distant organs and by the following [10–13]:
 — after an excision biopsy where diagnosis of skin mela-
noma is confirmed by histopathological examination, 
but not after extensive excision of the primary focus;
 — with a Breslow infiltration thickness ≥ 1.0 mm;
 — with (micro)ulceration on the melanoma surface re-
gardless of infiltration thickness or mitotic index 
≥ 1/mm2 [melanoma, with the primary focus being clas-
sified as in the pT1b-T4b category according to the TNM 
UICC/AJCC 2010 classification]. According to the data 
from the American Society of Surgical Oncology (SSO), 
American Society of Clinical Oncology (ASCO) [14, 15] 
and European Society for Medical Oncology (ESMO) 
[16], sentinel lymph node biopsy can be abandoned in 
pT1b melanomas of thickness up to 0.75 mm (however 
it should still be considered when finding an ulceration 
of the primary lesion) (Tab. I);
 — without clinical signs of metastases to regional lymph 
nodes and distant organs.
Sentinel lymph node biopsy is currently an indispensa-
ble method for assessing clinically occult metastases (earlier 
termed micrometastases) in lymph nodes [13–18]. In 1999, 
the WHO stated that sentinel lymph node biopsy should be 
the standard management in those patients with skin mela-
nomas without clinical signs of metastases to the regional 
lymph nodes. For these biopsies, preoperative lymphoscin-
tigraphy and intraoperative lymphoscintigraphy combined 
with staining should be performed. Sentinel lymph node 
biopsy should be undertaken after excision biopsy of the 
melanoma, simultaneously with radical excision of the re-
maining scar after the melanoma excision biopsy. Available 
data do not suggest any adverse effects on the prognosis 
following sentinel lymph node biopsy performed six weeks 
after the primary focus excision. The method’s accuracy 
relies on the collaboration between nuclear medicine spe-
cialists, surgeons and pathologists. Sentinel lymph node 
biopsy is a ‘minimally invasive’ diagnostic method in view 
of the low incidence of postoperative complications; both 
early and late.
The Multicenter Selective Lymphadenectomy Trial-1 
(MSLT) demonstrated that sentinel lymph node biopsy 
in patients with melanomas made it possible to detect 
groups at high risk of malignancies disseminating, helped 
to correctly determine the disease progression stage, pro-
vided excellent local control and enabled patients to be 
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qualified for clinical trials according to uniform criteria [17]. 
Nevertheless, the MSLT-1 trial showed no improvement of 
survival time to disease recurrence and total survival time 
in all patients subjects that underwent sentinel lymph 
node biopsy, compared with the test group . Despite this, 
the patient subgroup with lymph nodes metastases, had 
a significantly higher incidence of 10-year survival in tho-
se patients who had immediate lymphadenectomy after 
finding a sentinel lymph node metastasis compared with 
patients being so treated at later stages due to clinical-
ly evident metastases being detected (62.1% vs 41.5%; 
p = 0.006) [17].
Upon finding melanoma metastases in sentinel lymph 
node(s) (in the case of N > 0) after histopathological exa-
mination, a sufficiently adequate group of regional lymph 
nodes should be totally excised (complementary lympha-
denectomy) because in the remaining non-sentinel lymph 
nodes, melanoma metastases are found in about 20–30% 
patients [19].
Currently clinical trials are pending that are investiga-
ting whether the incidence of complementary lympha-
denectomy can be limited in those patients having small 
and clinically occult metastases in sentinel lymph nodes 
of diameter below 0.1 mm or of a diameter up to 0.4 mm 
when found in the subcapsular location without having 
any contemporaneously adverse effects on melanoma re-
currence [19]. 
Metastases to regional lymph nodes
It is commonly recognised that regional lymph nodes 
consist of one or two groups of lymph nodes situated at the 
lymphatic drainage regions closest to the primary lesion. 
This definition is applied to those lymph nodes that are in-
guinal-iliac, supraclavicular-axillary, cervical-supraclavicular, 
popliteal, antecubital, axillary-inguinal or bilateral axillary 
or inguinal.
Melanoma metastases to regional lymph nodes are as-
sessed by histopathological examination according to the 
pN parameter grades, whilst metastases located in lymph 
nodes beyond the regional lymphatic drainage by the M1a 
parameter [7].
Melanoma metastases to lymph nodes are qualified 
as a pN being above 0 (pN > 0) in each case when cells are 
detected after staining with haematoxylin and eosin or if 
based on an immunohistochemical reaction. Table II defi-
nes microscopic categories of metastases found in lymph 
nodes according to the 8th edition of the pTNM AJCC/UICC 
classification from 2017 [8]; changes having been made to 
the the 7th edition of the AJCC/UICC classification. The term 
‘micrometastases’ has now replaced ‘clinically occult’ and 
instead of ‘gross metastases’, the term ‘clinically evident’ has 
been introduced.
The 8th revision of the TNM/AJCC classification of 2017, 
uses the pN parameter to describe melanoma metastases 
in lymph nodes regardless of their size and number of mali-




Mitotic index Ulceration Additionally unfavourable factors*
< 1/mm2 ≥ 1/mm2 No Yes No Yes
≤ 0.5 No** No** No** No** No** No**
0.51–0.75 No** No** No** No** No** No**
0.76–1.0 To be considered Recommended To be considered Recommended To be considered Recommended
> 1.0–4.0 Recommended Recommended Recommended Recommended Recommended Recommended
> 4.0 Recommended Recommended Recommended Recommended Recommended Recommended
*Unfavourable factors include positive margin, involvement of lymphatic vessels, infiltration grade IV according to Clark** excepting ulceration of the primary focus.
Table II. Microscopic classification of melanoma metastases in lymph nodes according to the 8th edition of the pTNM AJCC/UICC classification 
of 2017 [8]
Type of metastasis to lymph 
node
Definition
Clinically occult Clinically and radiologically undetectable, but detected on histopathological examination after sentinel lymph 
node biopsy, in the preparation stained with haematoxylin and eosin or based on immunohistochemical 
reaction
In the 7th edition of the AJCC/UICC classification, these were described as micrometastases
Their size does not affect assessment of the N parameter but is accounted for in Additional Factors 
Recommended for Clinical Care according to the 8th edition of TNM/AJCC
Clinically evident Is clinically detectable and consusts of cells greater than 2 mm in size
In the 7th edition of the AJCC/UICC classification they were described as gross metastases
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gnant cells, nor of microsatellite or satellite foci or in-transit 
metastases in the lymph node(s) in numbers greater than 0 
(pN > 0). Patients with clinically occult metastases are classi-
fied as N1a, N2a, N3a, depending on the number of lymph 
nodes whenever microsatellite or satellite foci or in-transit 
metastases are not found, however if the afore mentioned 
satellite or in-transit foci are present but without metastases 
found in the lymph nodes, the N parameter is classified as 
N1c, N2c, N3c, respectively. In contrast, whenever there are 
clinically evident metastases in the lymph nodes but without 
microsatellite or satellite foci or in-transit metastases, the N 
parameter is then described as N1b. N2b, N3b, depending on 
the number of lymph nodes involved. The afore mentioned 
classification of the N parameter is significantly different 
between the 8th and 7th editions of the TNM AJCC/UICC 
classification (Tab. II) [7, 8].
Pathological examination procedure
For each cancer case the basic question is whether dis-
semination has occurred or if the cancer remains at the 
stage of local advancement. Metastases of melanoma can 
occur in the form of microsatellite or satellite foci, in transit 
metastases, metastases to lymph node(s) or distant meta-
stases. If sentinel lymph node(s) are involved, metastases to 
one or more lymph nodes occupied as the first along the 
lymphatic drainage route are most likely. Detecting even 
single melanoma cells in the sentinel lymph node usually 
provides the first evidence as to dissemination stage and 
radically changes any prognoses and ensuing therapeutic 
decisions. Therefore, it is vital that a full sentinel lymph node 
procedure/investigation is undertaken, in spite of the cost 
and extra effort required. 
Examining SLNs requires a more detailed diagnostic pro-
cedure than that routinely used for assessing lymph node 
groups by the pathologist. Pathological examination of the 
sentinel lymph node in melanomas consist of three stages:
 — histological examination of serially cut SLN cross-sec-
tions stained with haematoxylin and eosin;
 — complementary application of immunohistochemical 
methods using a specific panel of antibodies;
 — possible assessment of mRNA expression specific to a 
given malignancy, performed mainly for research pur-
poses [10, 11].
This examination is based on commonly accepted stan-
dards. The diagnosis of SLN is included in the pathomorpho-
logical report. Guidelines concerning lymph nodes exami-
ned in the course of melanoma have been developed by the 
College of American Pathologists (CAP) [7], the European 
Society of Pathology (ESP) [11] and in the Polish principles 
of diagnostic-therapeutic management; recently issued by 
the Polish Society of Pathologists [10, 21].
The basic recommendations of the afore mentioned 
societies concern the mode for preparing tissue material, 
methods of its examination and its clinical interpretation. 
They can be summarised as in the sections below.
A. Preparation of SLN tissue material
Surgical procedure
Sentinel lymph nodes should be sent to the pathology 
laboratory either fixed in 10% buffered formalin or non-
Figure 1. Mode of sentinel lymph node examination according to the British guidelines [22]
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-fixed, upon which they are ready to undergo specialised 
PCR methods testing (polymerase chain reaction). It is 
recommended that the lymph node is denoted by means 
of threads or metal clips at the site where the greatest 
amount of the marker has accumulated. Intraoperative 
examination of a SLN is not indicated in melanoma. Pre-
paring frozen tissue sections and cutting in a cryostat can 
however damage or destroy the malignant cells [5, 13]. It is 
therefore considered that the gold standard in melanoma 
is when examining sentinel lymph nodes that have been 
fixed in formalin and embedded in paraffin. Cytological 
examination is not recommended since macrophages 
filled with brown pigment cannot be unequivocally di-
stinguished from melanocytes nor can the location of 
melanoma cells be found in the lymph node. Cytological 
material is also of no use in performing immunohistoche-
mical tests for confirming or ruling out the diagnosis of 
a metastasis [22].
Gross examination when preparing sections
Each lymph node should be cut along its lengthwise 
axis. The recommended thickness of the lymph node cross-
-sections are 3 to 5 mm. The cross-section should contain 
adipose tissue adjacent to the lymph node. Each lymph node 
should be taken whole and placed into separate containers; 
two or more lymph nodes are not allowed to be together. 
If a single lymph node cannot be fitted into one container 
it should be divided into several separate containers and 
marked appropriately that this is so the case.
European guidelines recommend cutting a sentinel 
lymph node, according to Cochrane’s original protocol, into 
two lobes cutting through the lymph node’s hilum [23]. CAP 
guidelines recommend taking a small and whole lymph 
node (of diameter below 5 mm) or for larger ones they 
allow serial layer cutting into 2-mm slices perpendicular to 
the node lengthwise axis, termed ‘breadloafing’ [7]. Figure 1 
depicts how cross-sections through the hilum of a sentinel 
lymph node are made and then placed into a container with 
the cross-sectional surface facing down. Figure 2 shows both 
methods of taking sections according to CAP guidelines. 
The British proposal, accepted as the European Guidelines, 
recommends cutting six pairs of HE-stained tissue sections 
at 50 µm intervals. That method has now been accepted 
by EORTC.
B. Microscopic examination of SLN
These depend on determining the presence of, the 
size and location of metastases in the lymph node (Fig. 3). 
Melanoma cells lying singly or in small clusters are most 
frequently located in nodal sinuses under the capsule 
(58% cases). They are less frequently found in the lymph 
node parenchyma, in the fibrous capsule or in perinodal 
tissues (less than 5% cases). Melanoma metastases are 
found in about 20% of sentinel lymph nodes [24]. In 16% 
cases, they can be already detected by routine staining 
with haematoxylin and eosin, whilst in 4% they require 
detection and confirmation by immunohistochemical 
tests [24]. Out of the recommended tests of melanoma 
markers S100, HMB-45 (Fig. 4), MART-1 and tyrosinase, at 
least one of these should be carried out. The MITF antibo-
dy is not recommended because of its positive reaction 
with macrophages [25]. A differential diagnosis requires 
distinguishing melanocytes from macrophages, dendritic 
cells and naevus cells located subcapsularly. In cases of 
spindle cell melanoma, the S100 marker is recommended, 
since this rare melanoma type may not express HMB-45 
nor MART-1 [10, 11, 21].
If melanoma metastases are found in sentinel lymph 
node(s), then the following should apply:
 — the number of lymph nodes found and number of nodes 
with metastases should be reported;
 — the following microscopic features of metastases in sen-
tinel lymph node(s) should be determined:
•	 the greatest dimensions of the metastasis/metastases,
•	 their location (subcapsular, intramedullary, mixed or 
diffuse),
Figure 2. American recommendations concerning performing cross-sections through sentinel lymph node [4]
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Figure 3. Location of melanoma metastases in sentinel lymph node: A — subcapsular, B — mixed, subcapsular and intramedullary, C — multifocal, 
D — extending to perinodal tissues acc. to [4]
Figure 4. Location of melanoma metastases in subcapsular region. Immunohistochemical staining HMB45
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•	 penetration into perinodal adipose tissue,
•	 penetration into adipose tissue,
•	 vasculature involvement. 
In summary it should be said that due to a lack of 
consensus whenever sentinel lymph node are studied, 
the aforementioned guidelines constitute an optimal al-
gorithm of management thereby making it possible that 
the highest sensitivity and specificity of an examination 
is maintained. 
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